Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach